美国 · SEC FORM 4
Generate Biomedicines, Inc.
GENB · Nasdaq · CIK 0002100782 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
1 同一窗口内观察到的 Form 4 交易行
1 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-04 · Nally Michael.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 7,417,094
- 上期报告
- 7,180,013
- 日均成交量
- 1,289,467
- 回补天数
- 5.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Nally Michael | 买入 (P) | Common Stock | 20,000 | USD 12.00 | USD 240,000 | SEC 申报 ↗ |
| 2026-03-02 | Silvers Jason | 买入 (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC 申报 ↗ |
| 2026-03-02 | Mendillo Jane L | 买入 (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC 申报 ↗ |
| 2026-03-02 | Grous Beth | 买入 (P) | Common Stock | 300 | USD 16.00 | USD 4,800 | SEC 申报 ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN II, L.P.; Flagship Pioneering Fund VI, L.P.; Flagship Pioneering Fund VII, L.P.; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship VentureLabs VI LLC; Nutritional Health LTP Fund, L.P. | 买入 (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC 申报 ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN General Partner LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Nutritional Health LTP Fund General Partner LLC | 买入 (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC 申报 ↗ |
Form 4 申报证据
18 transaction lines in the latest 365-day window; 18 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | ARNOLD FRANCES | 卖出 (S) | Common Stock | 1,000 | USD 16.00 | USD 16,000 | SEC 申报 ↗ |
| 2026-03-04 | Nally Michael | 买入 (P) | Common Stock | 20,000 | USD 12.00 | USD 240,000 | SEC 申报 ↗ |
| 2026-03-02 | Silvers Jason | 买入 (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC 申报 ↗ |
展开近期 Form 4 证据 (11 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | ARNOLD FRANCES | 卖出 (S) | Common Stock | 1,000 | USD 16.00 | USD 16,000 | SEC 申报 ↗ |
| 2026-03-04 | Nally Michael | 买入 (P) | Common Stock | 20,000 | USD 12.00 | USD 240,000 | SEC 申报 ↗ |
| 2026-03-02 | Silvers Jason | 买入 (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC 申报 ↗ |
| 2026-03-02 | Nally Michael | C (C) | Common Stock | 658,327 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-02 | Mendillo Jane L | 买入 (P) | Common Stock | 1,500 | USD 16.00 | USD 24,000 | SEC 申报 ↗ |
| 2026-03-02 | Grous Beth | 买入 (P) | Common Stock | 300 | USD 16.00 | USD 4,800 | SEC 申报 ↗ |
| 2026-03-02 | Bancel Stephane | C (C) | Common Stock | 724,160 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN II, L.P.; Flagship Pioneering Fund VI, L.P.; Flagship Pioneering Fund VII, L.P.; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship VentureLabs VI LLC; Nutritional Health LTP Fund, L.P. | 买入 (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC 申报 ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN II, L.P.; Flagship Pioneering Fund VI, L.P.; Flagship Pioneering Fund VII, L.P.; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship VentureLabs VI LLC; Nutritional Health LTP Fund, L.P. | C (C) | Common Stock | 30,191,407 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN General Partner LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Nutritional Health LTP Fund General Partner LLC | 买入 (P) | Common Stock | 1,562,500 | USD 16.00 | USD 25,000,000 | SEC 申报 ↗ |
| 2026-03-02 | AFEYAN NOUBAR; FPN General Partner LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Nutritional Health LTP Fund General Partner LLC | C (C) | Common Stock | 30,191,407 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | GENB |
| CIK | 0002100782 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 18 transaction lines from 2026-03-02 to 2026-09-01 7 P purchase lines · 1 S sale lines · 10 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.